Cue Biopharma's Total Assets for the quarter that ended in Dec. 2023 was $61.53 Mil.
During the past 12 months, Cue Biopharma's average Total Assets Growth Rate was -13.20% per year.
During the past 3 years, the average Total Assets Growth Rate was -3.90% per year.
During the past 5 years, the average Total Assets Growth Rate was 14.10% per year.
During the past 9 years, Cue Biopharma's highest 3-Year average Total Assets Growth Rate was 110.70%. The lowest was -3.90%. And the median was 54.10%.
The historical data trend for Cue Biopharma's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Cue Biopharma's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Cue Biopharma's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Cue Biopharma Total Assets Related Terms
Thank you for viewing the detailed overview of Cue Biopharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Cue Biopharma (Cue Biopharma) Business Description
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CUE has been successfully added to your 